GlassScriptPhysician profile
David Michael Tremblay
NPI 1356636492
$4,973.20
in general payments reported to CMS, 2019-2025
19 companies · $772 in 2025
The $772 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,149 · 2020: $752 · 2021: $223 · 2022: $299 · 2023: $259 · 2024: $520 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,551.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,550.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,824.85 | 2019-2025 | Wavelight Refractive Suite, Centurion, Wavelight Plus |
| Johnson & Johnson Surgical Vision, INC. | $1,228.06 | 2019-2023 | Tecnis Simplicity, Catalys System |
| Allergan, INC. | $675.79 | 2019-2021 | |
| Sight Sciences, INC. | $297.91 | 2024-2025 | Omni Surgical System |
| Abbvie INC. | $247.17 | 2022-2025 | Durysta |
| Tarsus Pharmaceuticals, INC. | $139.79 | 2024 | Xdemvy |
| Beaver-Visitec International, INC. | $105.65 | 2019-2020 | |
| Glaukos Corporation | $101.48 | 2019 | |
| Inspire Medical Systems, INC. | $71.08 | 2024-2025 | Inspire |
| Sun Pharmaceutical Industries INC. | $52.65 | 2020-2024 | |
| Shire North American Group INC | $40.60 | 2019 | |
| Eyevance Pharmaceuticals LLC | $38.33 | 2019-2022 | |
| Harrow Eye, LLC | $35.53 | 2025 | Vevye |
| Oyster Point Pharma, INC. | $26.73 | 2022 | |
| Amgen INC. | $21.13 | 2025 | Tepezza |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $21.06 | 2022 | |
| Biotissue Holdings INC. | $16.52 | 2019 | |
| Dompe US, INC. | $15.37 | 2019 | |
| Kala Pharmaceuticals, INC. | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Tremblay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.